Expression of MIR17HG in meningioma and its clinical significance
YANG Zhen
SONG Jing-jun
YANG Wei
XING Zhi-guo
Abstract：Objective To explore the expression and clinical significance of the miR-17-92 gene cluster host gene(MIR17HG)in meningiomas.Methods A total of 115 meningioma specimens were collected from November 2018 to March 2022,and 80 non-tumor brain tissues removed during decompressive craniectomy for craniocerebral injury were selected as the control group.The level of MIR17HG was detected by real-time fluorescence quantitative PCR.The patients with meningioma were followed up until November 30,2023,or death,and progression-free survival(PFS)and overall survival(OS)were recorded.Results Compared with the control group,the level of MIR17HG in meningioma tissues was significantly increased(P<0.05);moreover,the level of MIR17HG in WHO gradeⅡand Ⅲ meningioma tissues was significantly higher than that in WHO grade Ⅰ meningioma(P<0.05).The postoperative follow-up period was 0.5 to 6.0 years,with a median follow-up time of 3.5 years;28 cases of tumor recurrence/progression and 14 deaths were recorded.Multivariate Cox regression analysis revealed that high expression of MIR17HG was an independent risk factor for poor prognosis in patients with meningioma(OR=1.734;95%CI 1.304～2.305;P<0.001).Survival curve analysis demonstrated that the PFS(5.30±0.18 years vs.3.94±0.31 years)and the OS(5.80±0.09 years vs.4.75±0.27 years)of meningiomas with low expression of MIR17HG were significantly prolonged(P<0.05).Conclusion The expression level of MIR17HG in meningiomas is significantly upregulated,and its high expression indicates a poor prognosis for meningiomas.
Keywords：MeningiomaHost gene of miR-17-92 gene cluster(MIR17HG)Prognosis
Publication Date：2024-12-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 729-733 )